[The treatment of metastasizing hypernephroid (renal cell) carcinoma with medroxyprogesterone acetate (Clinovir) (author's transl].
15 patients with distant metastases of hypernephroid carcinoma were treated with medroxyprogesterone acetate (usually 300 mg daily by mouth). In 5 patients the metastases showed slower growth, remained stationary or regressed somewhat under this treatment. But a complete regression of metastases could not be obtained. The treatment was very well tolerated. Monitoring the transaminases and alkaline phosphatase during treatment is to be recommended.
D000230:Adenocarcinoma / Q000188:drug therapy*; D000328:Adult; D000368:Aged; D000410:Alanine Transaminase / Q000097:blood; D000469:Alkaline Phosphatase / Q000097:blood; D001219:Aspartate Aminotransferases / Q000097:blood; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy*; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008525:Medroxyprogesterone / Q000627:therapeutic use*; D008875:Middle Aged; D009362:Neoplasm Metastasis
D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D000469:Alkaline Phosphatase; D008525:Medroxyprogesterone
Die Behandlung des metastasierten hypernephroiden Nierenkarzinoms mit Medroxy-progesteronazetat (Clinovir).